Venture Life Group PLC (LON:VLG)‘s stock had its “buy” rating reiterated by analysts at Panmure Gordon in a report issued on Wednesday. They presently have a GBX 128 ($1.67) price objective on the stock. Panmure Gordon’s price target indicates a potential upside of 134.86% from the stock’s previous close.

Separately, Beaufort Securities restated a “speculative buy” rating on shares of Venture Life Group PLC in a report on Monday, August 1st.

Shares of Venture Life Group PLC (LON:VLG) traded up 3.81% during trading on Wednesday, reaching GBX 54.50. 17,500 shares of the company traded hands. The company has a 50-day moving average of GBX 51.62 and a 200-day moving average of GBX 56.45. Venture Life Group PLC has a 12 month low of GBX 43.00 and a 12 month high of GBX 81.92. The stock’s market capitalization is GBX 18.75 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with's FREE daily email newsletter.